The French drugmaker is looking to dealmaking after some experimental drugs missed their goals in clinical studies or were ...

Shares of Dynavax Technologies (NASDAQ: DVAX) popped on Wednesday after the vaccine maker struck a deal to be acquired by Sanofi (NASDAQ: SNY). As of 3:00 p.m. EST, Dynavax's stock price was up more ...

The deal gives Sanofi access to Dynavax’s approved hepatitis B vaccine, News.Az reports, citing Reuters. This acquisition ...

Dynavax's adult hepatitis B vaccine HEPLISAV-B is currently marketed in the US and is differentiated by its two-dose regimen over one month, which enables high levels of seroprotection faster than ...

Here are some of the stocks making notable moves in Wednesday's premarket action: Dynavax Technologies stock is up 37% after ...

The Dow Jones Industrial Average climbed 0.6% to 48,731.16, while the S&P 500 added 0.32% to close at 6,932.05.

Sanofi has announced an agreement to acquire U.S.-based vaccines company Dynavax Technologies in an all-cash transaction ...

French pharma major Sanofi today revealed it has agreed to acquire Dynavax Technologies, a US vaccines company with a ...

Sanofi acquires Dynavax for $2.2B, boosting its vaccine portfolio with HEPLISAV-B and a shingles candidate. Click for my ...

The French pharma major has started a $15.50 per share cash tender offer for Emeryville, California-based Dynavax, which ...

Investing.com -- French pharmaceutical giant Sanofi (EPA:SASY) said it plans to acquire Dynavax Technologies Corporation (NASDAQ:DVAX) for $15.50 per share in cash, valuing the vaccines company at ...

Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline Paris, December 24, 2025.